Medlab Clinical Receives US patent for NanoCelle
- The US Patent & Trademark Office (USPTO) grants patent protection for Medlab Clinical’s (MDC) NanoCelle technology in the United States
- NanoCelle is Medlab’s drug delivery nanotechnology that aims to overcome the current obstacles surrounding drug delivery
- It creates nano-sized water-soluble particles that enable optimised and standardised delivery of medicines
- Patents have now been granted in Australia, New Zealand, Canada, the United States and more than 35 European countries
- Medlab is up 12.5 per cent on the market with shares trading at 18 cents
